further Publications

Prof. Dr. Guus Rimmelzwaan

Dam, S., Tscherne, A., Engels, L., Sutter, G., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2025). Design and evaluation of a poly-epitope based vaccine for the induction of influenza A virus cross-reactive CD8 + T cell responses. Scientific Reports, 15, Article 10586. https://doi.org/10.1038/s41598-025-95479-9
read more
Guilfoyle, K., Mirolo, M., van, van der, Lombardo, M. S., Störk, T., Rimmelzwaan, G., Ludlow, M., & Osterhaus, A. (2025). Susceptibility of calf lung slice cultures to H5N1 influenza virus. Emerging Microbes & Infections, 14(1), Article 2432368. https://doi.org/10.1080/22221751.2024.2432368
read more
Guilfoyle, K., Mirolo, M., de Waal, L., van Amerongen, G., van der Net, G., Störk, T., Lombardo, M. S., Baumgärtner, W., Bjarnason, Á., Jóhannsdóttir, H. B., Rimmelzwaan, G. F., Ludlow, M., & Osterhaus, A. D. M. E. (2025). Highly pathogenic avian influenza virus A/H5N1 subclade 2.3.4.4 b isolated from a European grey seal (Halichoerus grypus) is highly virulent in ferrets. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiaf348
read more
Quiñones-Parra, S. M., Gras, S., Nguyen, T. H. O., Farenc, C., Szeto, C., Rowntree, L. C., Chaurasia, P., Sant, S., Boon, A. C. M., Jayasinghe, D., Rimmelzwaan, G. F., Petersen, J., Doherty, P. C., Uldrich, A. P., Littler, D. R., Rossjohn, J., & Kedzierska, K. (2025). Molecular determinants of cross-strain influenza A virus recognition by αβ T cell receptors. Science Immunology, 10(104), Article eadn3805. https://doi.org/10.1126/sciimmunol.adn3805
read more
Agac, A., Meineke, R., Ludlow, M., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). RSV infection induces a proinflammatory immune response in primary monocytes. In 17th Graduate School Days: 22/23 November 2024 : abstract book (Zoo T 18). Stiftung Tierärztliche Hochschule Hannover.
read more
Aregay, A., Slunečko, J., Korva, M., Bogovic, P., Resman Rus, K., Knap, N., Beicht, J., Kubinski, M., Saletti, G., Avšič-Županc, T., Steffen, I., Strle, F., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Tick-borne encephalitis vaccine breakthrough infections induce aberrant T cell and antibody responses to non-structural proteins. Npj Vaccines, 9, Article 141. https://doi.org/10.1038/s41541-024-00936-7
read more
Aregay, A., Slunečko, J., Bogovic, P., Korva, M., Resman Rus, K., Knap, N., Beicht, J., Kubinski, M., Saletti, G., Steffen, I., Strle, F., Avšič-Županc, T., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Poor virus-specific T-cell responses early after tick-borne encephalitis virus infection correlate with disease severity. Emerging Microbes & Infections, 13(1), Article 2317909. https://doi.org/10.1080/22221751.2024.2317909
read more
Aregay, A., Slunečko, J., Bogovic, P., Korva, M., Rus, K. R., Knap, N., Beicht, J., Kubinski, M., Saletti, G., Steffen, I., Sterle, F., Avšič-Županc, T., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Poor virus-specific T-cell responses early after tick-borne encephalitis virus infection correlate with disease severity. In 8th World One Health Congress: abstract book (1089). https://globalohc.org/8WOHC
read more
Kubinski, M., Beicht, J., Gerlach, T., Aregay, A., Osterhaus, A. D. M. E., Tscherne, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2024). Immunity to tick-borne encephalitis virus NS3 protein induced with a recombinant modified vaccinia virus Ankara fails to afford mice protection against TBEV infection. Vaccines, 12(1), Article 105. https://doi.org/10.3390/vaccines12010105
read more
Leroux-Roels, I., Prajeeth, K. C., Aregay, A., Nair, N., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., Kardinahl, S., Pelz, S., Bauer, S., D’Onofrio, V., Alhatemi, A., Jacobs, B., De Boever, F., Porrez, S., Waerlop, G., Punt, C., Hendriks, B., von, van de, et al. (2024). Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against rift valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial. The Lancet: Infectious Diseases, 24(11), 1245–1253. https://doi.org/10.1016/S1473-3099(24)00375-X
read more

Prajeeth K. Chittappen, PhD

Schweitzer, F., Letoha, T., Osterhaus, A., & Prajeeth, C. K. (2025). Impact of tick-borne orthoflaviviruses infection on compact human brain endothelial barrier. International Journal of Molecular Sciences, 26(5), Article 2342. https://doi.org/10.3390/ijms26052342
read more
Schweitzer, F., Schröder, L.-J., Friedrichs, A., Gudi, V., Skripuletz, T., Steffen, I., Palus, M., Růžek, D., Osterhaus, A., & Prajeeth, C. K. (2025). Mosquito- and tick-borne orthoflaviviruses cross an in vitro endothelial-astrocyte barrier. Frontiers in Cellular and Infection Microbiology, 15, Article 1624636. https://doi.org/10.3389/fcimb.2025.1624636
read more
Kubinski, M., Beicht, J., Gerlach, T., Aregay, A., Osterhaus, A. D. M. E., Tscherne, A., Sutter, G., Prajeeth, C. K., & Rimmelzwaan, G. F. (2024). Immunity to tick-borne encephalitis virus NS3 protein induced with a recombinant modified vaccinia virus Ankara fails to afford mice protection against TBEV infection. Vaccines, 12(1), Article 105. https://doi.org/10.3390/vaccines12010105
read more
Leroux-Roels, I., Prajeeth, K. C., Aregay, A., Nair, N., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., Kardinahl, S., Pelz, S., Bauer, S., D’Onofrio, V., Alhatemi, A., Jacobs, B., De Boever, F., Porrez, S., Waerlop, G., Punt, C., Hendriks, B., von, van de, et al. (2024). Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against rift valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial. The Lancet: Infectious Diseases, 24(11), 1245–1253. https://doi.org/10.1016/S1473-3099(24)00375-X
read more
Nair, N., Chitappen Kandiyil, P., & Rimmelzwaan, G. F. (2024). Innate immune responses induced by attenuated Rift Valley Fever Virus (RVFV) infection in human PBMC. In 17th Graduate School Days: 22/23 November 2024 : abstract book (Zoo T 07). 17th Graduate School Days, 22.11.2024 – 23.11.2024. Stiftung Tierärztliche Hochschule Hannover.
read more
Nair, N., Wichgers Schreur, P. J., Osterhaus, A. D. M. E., Rimmelzwaan, G. F., & Chittappen Kandiyil, P. (2024). Characterisation of innate immune responses induced by the Rift Valley Fever Virus (RVFV) in humans. International One Health Symposium 2024, 17.10.2024 - 19.10.2024.
read more
Nair, N., Wichgers Schreur, P. J., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Chittappen Kandiyil, P. (2024). Innate immune responses induced by Rift Valley Fever Virus (RVFV) infection in human PBMC. Conference title: 23rd Workshop Immunobiology of Viral Infections, 28.10.2024 ‒ 30.10.2024.
read more
Prajeeth, C. K., Zdora, I., Saletti, G., Friese, J., Gerlach, T., Wilken, L., Beicht, J., Kubinski, M., Puff, C., Baumgärtner, W., Kortekaas, J., Wichgers Schreur, P. J., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2024). Immune correlates of protection of the four-segmented Rift Valley fever virus candidate vaccine in mice. Emerging Microbes & Infections, 13, Article 2373313. https://doi.org/10.1080/22221751.2024.2373313
read more
Schweitzer, F., Schröder, L.-J., Gudi, V., Steffen, I., Palus, M., Růžek, D., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Chittappen Kandiyil, P. (2024). From blood to brain: in vitro studies on orthoflavivirus neuroinvasion. In 17th Graduate School Days: 22/23 November 2024 : abstract book (ZSN T 06). Stiftung Tierärztliche Hochschule Hannover.
read more
Beicht, J., Kubinski, M., Zdora, I., Puff, C., Biermann, J., Gerlach, T., Baumgärtner, W., Sutter, G., Osterhaus, A., Prajeeth, C. K., & Rimmelzwaan, G. F. (2023). Induction of humoral and cell-mediated immunity to the NS1 protein of TBEV with recombinant Influenza virus and MVA affords partial protection against lethal TBEV infection in mice. Frontiers in Immunology, 14, Article 1177324. https://doi.org/10.3389/fimmu.2023.1177324
read more

Husni Elhabesh, PhD

Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2023). FDA-approved Abl/EGFR/PDGFR kinase inhibitors show potent efficacy against pandemic and seasonal influenza A virus infections of human lung explants. iScience, 26(4), Article 106309. https://doi.org/10.1016/j.isci.2023.106309
read more
Meineke, R. (2022). Inhibition of Host Kinase Activity: Effects on Influenza A Virus Infection and Host Cell Signaling. https://nbn-resolving.org/urn:nbn:de:gbv:95-117384
read more
Meineke, R., Stelz, S., Busch, M., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2022). FDA-approved inhibitors of RTK/Raf signaling potently impair multiple steps of in vitro and ex vivo influenza A virus infections. Viruses, 14(9), Article 2058. https://doi.org/10.3390/v14092058
read more
Becker, T., Elbahesh, H., Reperant, L. A., Rimmelzwaan, G. F., & Osterhaus, A. D. M. E. (2021). Influenza vaccines: successes and continuing challenges. The Journal of Infectious Diseases, 224(Supplement 4), 405–S419. https://doi.org/10.1093/infdis/jiab269
read more
Palacios-Pedrero, M. Á., Osterhaus, A. D. M. E., Becker, T., Elbahesh, H., Rimmelzwaan, G. F., & Saletti, G. (2021). Aging and options to halt declining immunity to virus infections. Frontiers in Immunology, 12, Article 681449. https://doi.org/10.3389/fimmu.2021.681449
read more
Ricke-Hoch, M., Stelling, E., Lasswitz, L., Gunesch, A. P., Kasten, M., Zapatero-Belinchón, F. J., Brogden, G., Gerold, G., Pietschmann, T., Montiel, V., Balligand, J.-L., Facciotti, F., Hirsch, E., Gausepohl, T., Elbahesh, H., Rimmelzwaan, G. F., Höfer, A., Kühnel, M. P., Jonigk, D., et al. (2021). Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. PLoS ONE, 16(8), Article e0255335. https://doi.org/10.1371/journal.pone.0255335
read more
Di, H., Elbahesh, H., & Brinton, M. A. (2020). Characteristics of human OAS1 isoform proteins. Viruses, 12(2: 152). https://doi.org/10.3390/v12020152
read more
Meineke, R., Werlein, C., Kühnel, M., Jonigk, D., Rimmelzwaan, G. F., & Elbahesh, H. (2020). Differential susceptibility of pandemic H1N1 and seasonal H3N2 Influenza A viruses to clinically-approved small molecule kinase inhibitors. In Stiftung Tierärztliche Hochschule Hannover (Ed.), 13th Graduate School Days: 20/21 November 2020 / Stiftung Tierärztliche Hochschule Hannover (Zoo V 05). Stiftung Tierärztliche Hochschule Hannover.
read more
Saletti, G., Gerlach, T., Jansen, J. M., Molle, A., Elbahesh, H., Ludlow, M., Li, W., Bosch, B.-J., Osterhaus, A. D. M. E., & Rimmelzwaan, G. F. (2020). Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63. Scientific Reports, 10: 21447. https://doi.org/10.1038/s41598-020-78506-9
read more
Bergmann, S., & Elbahesh, H. (2019). Targeting the proviral host kinase, FAK, limits influenza a virus pathogenesis and NFkB-regulated pro-inflammatory responses. Virology, 534, 54–63. https://doi.org/10.1016/j.virol.2019.05.020
read more